Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index; 37 of the 77 sources its claims cite were checked for support.

Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis

Open access

Abstract

Background: Type 2 diabetes (T2D) is strongly linked to chronic inflammation and oxidative stress, which drive cardiovascular complications. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) demonstrate cardioprotective benefits that may extend beyond glycemic control, but their effects on key inflammatory and oxidative stress biomarkers compared to other glucose-lowering medications remain inconsistently reported across individual studies. Methods: A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted. Databases were searched for RCTs comparing GLP-1 RAs against other antidiabetic drugs or placebo in adults with T2D, reporting changes in inflammatory biomarkers (C-reactive protein [CRP], interleukin-6 [IL-6], tumor necrosis factor-alpha [TNF-α]) or the oxidative stress marker malondialdehyde (MDA). Data were pooled using a random-effects model, and outcomes were stratified by comparator type (placebo, insulin, other oral antidiabetic drugs [OADs]). Results: Forty RCTs (n=6029 participants) were included. GLP-1 RA therapy significantly reduced CRP levels compared to placebo (SMD = -0.59; 95% CI: -0.84 to -0.34) and other OADs (SMD = -1.06; 95% CI: -1.64 to -0.47). A significant reduction in TNF-α was observed versus placebo (SMD = -0.61; 95% CI: -0.89 to -0.32) and oral antidiabetic drugs add on (SMD = -1.62; 95% CI: -2.86 to -0.38). Data for MDA were limited and showed a non-significant trend toward reduction. GLP-1 RAs also significantly reduced IL-6 versus insulin (SMD = -0.24; 95% CI: -0.46 to -0.02). While significant heterogeneity was noted across the analyses, sensitivity analyses confirmed a consistent direction of effect, reinforcing the class-wide anti-inflammatory properties of GLP-1 RAs. Conclusion: GLP-1 RAs significantly improve key biomarkers of systemic inflammation (CRP, TNF-α) in patients with T2D compared to various active comparators and placebo. These pleiotropic effects provide a mechanistic rationale for their cardiovascular benefits and support their use as a multifaceted therapeutic strategy in T2D management. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251157476, identifier CRD420251157476.

Overview

CoChat Summary

## TL;DR

This systematic review and meta-analysis of 40 randomized controlled trials (6,029 participants) found that GLP-1 receptor agonists generally lowered inflammatory biomarkers in adults with type 2 diabetes, with the clearest and most consistent benefit seen for CRP. Effects on IL-6, TNF-α, and MDA were more mixed and often depended on comparator and outlier studies.

## Key findings

  • Across 40 RCTs involving 6,029 participants, GLP-1 RAs reduced CRP versus placebo (SMD = -0.59; 95% CI: -0.84 to -0.34) and versus other oral antidiabetic drugs (SMD = -1.06; 95% CI: -1.64 to -0.47).
  • TNF-α was reduced versus placebo (SMD = -0.61; 95% CI: -0.89 to -0.32) and versus oral antidiabetic drugs when used as add-on therapy (SMD = -1.62; 95% CI: -2.86 to -0.38), but other TNF-α comparisons were non-significant and highly heterogeneous.
  • IL-6 was significantly reduced versus insulin (SMD = -0.24; 95% CI: -0.46 to -0.02), while other IL-6 comparisons were non-significant or sensitive to outlier removal.
  • MDA showed a non-significant trend toward reduction versus insulin in the main analysis, but after sensitivity analysis excluding an outlier the pooled effect became significant (SMD = -0.73; 95% CI: -1.07 to -0.39).

## Methods

  • Systematic review and meta-analysis of randomized controlled trials comparing GLP-1 receptor agonists with placebo, insulin, or other glucose-lowering drugs in adults with type 2 diabetes.
  • Searches were conducted in PubMed/MEDLINE, Embase, Cochrane CENTRAL, and Web of Science from inception to August 1, 2025; 40 RCTs met inclusion criteria.
  • Outcomes were pooled using random-effects models, stratified by comparator type, with risk of bias assessed using Cochrane RoB 2 and sensitivity analyses performed to exclude outliers/high-bias studies.

## Limitations

  • The paper states that substantial statistical heterogeneity was the main limitation, especially for TNF-α, IL-6, and MDA, with I² often above 80–90%.
  • The text notes limited generalizability because studies were geographically clustered, with 19 of 40 trials from China, and most trials had short follow-up (median 12–26 weeks).
  • The study-level meta-analysis could not fully account for confounding from concurrent drugs, dietary treatments, and uncontrolled comorbidities, and publication bias could not be ruled out; these are stated in the paper.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fendo.2025.1734549

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 (A) Forest plot of standardized mean difference (SMD) in C-reactive protein (CRP) levels for GLP-1 Receptor Agonists versus Placebo. (B) Forest plot of SMD in CRP levels for GLP-1 Receptor Agonists versus Insulin. (C) Forest plot of SMD in CRP levels for GLP-1 Receptor Agonists versus other Oral Antidiabetic Drugs (OADs).
Figure 1 (A) Forest plot of standardized mean difference (SMD) in C-reactive protein (CRP) levels for GLP-1 Receptor Agonists versus Placebo. (B) Forest plot of SMD in CRP levels for GLP-1 Receptor Agonists versus Insulin. (C) Forest plot of SMD in CRP levels for GLP-1 Receptor Agonists versus other Oral Antidiabetic Drugs (OADs).CC BY · PubMed Central
Figure 2 (A) Forest plot of SMD in Interleukin-6 (IL-6) levels for GLP-1 Receptor Agonists versus Oral Antidiabetic Drugs. (B) Forest plot of SMD in IL-6 levels for GLP-1 Receptor Agonists versus Insulin. (C) Forest plot of SMD in IL-6 levels for GLP-1 RA add-on therapy versus existing Oral Antidiabetic Drug regimen.
Figure 2 (A) Forest plot of SMD in Interleukin-6 (IL-6) levels for GLP-1 Receptor Agonists versus Oral Antidiabetic Drugs. (B) Forest plot of SMD in IL-6 levels for GLP-1 Receptor Agonists versus Insulin. (C) Forest plot of SMD in IL-6 levels for GLP-1 RA add-on therapy versus existing Oral Antidiabetic Drug regimen.CC BY · PubMed Central
Figure 3 (A) Forest plot of SMD in Tumor Necrosis Factor-alpha (TNF-α) levels for GLP-1 Receptor Agonists versus Placebo. (B) Forest plot of SMD in TNF-α levels for GLP-1 Receptor Agonists versus Insulin. (C) Forest plot of SMD in TNF-α levels for GLP-1 Receptor Agonists versus other Oral Antidiabetic Drugs. (D) Forest plot of SMD in TNF-α levels for GLP-1 RA add-on therapy.
Figure 3 (A) Forest plot of SMD in Tumor Necrosis Factor-alpha (TNF-α) levels for GLP-1 Receptor Agonists versus Placebo. (B) Forest plot of SMD in TNF-α levels for GLP-1 Receptor Agonists versus Insulin. (C) Forest plot of SMD in TNF-α levels for GLP-1 Receptor Agonists versus other Oral Antidiabetic Drugs. (D) Forest plot of SMD in TNF-α levels for GLP-1 RA add-on therapy.CC BY · PubMed Central
Figure 4 (A) Forest plot of SMD in interleukin-6 (IL-6) levels for GLP-1 receptor agonists versus oral antidiabetic drugs. (B) Forest plot of SMD in IL-6 levels for GLP-1 receptor agonists versus insulin. (C) Forest plot of SMD in IL-6 levels for GLP-1 RA add-on therapy versus existing oral antidiabetic drug regimen.
Figure 4 (A) Forest plot of SMD in interleukin-6 (IL-6) levels for GLP-1 receptor agonists versus oral antidiabetic drugs. (B) Forest plot of SMD in IL-6 levels for GLP-1 receptor agonists versus insulin. (C) Forest plot of SMD in IL-6 levels for GLP-1 RA add-on therapy versus existing oral antidiabetic drug regimen.CC BY · PubMed Central

Verification

Claims the paper makes

23 Valid · 3 Not valid · 14 Not checked · 115 Own results and interpretations

76 more claims · 9 with their cited sources checked

Create a free account to see all 155 claims and to verify the 4 references still open.

See all claims — free account
  • It may state two separate claims as one. 64
  • Probably not a substantial claim. 26
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 54 references

Research works printed but not linked: 2

  1. Wang, 2020, Comparison between the effects of sitagliptin and liraglutide on blood glucose and cognitive function of patients with both type 2 diabetes mellitus and post-stroke mild cognitive impairment, Int J Clin Exp Med, 13
  2. Suzuki, 2014, Greater efficacy and improved endothelial dysfunction in untreated type 2 diabetes with liraglutide versus sitagliptin, Dokkyo J Med Sci, 41

Cited by

See all 4

Metadata

Authors
Alrasheed, T., Mostafa, M. E. A., Madkhali, M. A., & Khairy, H. A.
Affiliations
  • University of Tabuk (SA)
  • Jazan University (SA)
  • Imam Mohammad ibn Saud Islamic University (SA)
Corresponding author
Khairy, Hesham A
Venue
Frontiers in Endocrinology
Published
2026-01-15
Volume
16
Pages
1734549-1734549
ISSN
1664-2392 (ISSN-L)
OpenAlex
W7124242929
Cited by
4
References
54
Citations by year
2026: 4
FWCI
4.24
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Endocrinology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
GLP-1 receptor agonists, type 2 diabetes, inflammation, oxidative stress, C-reactive protein, TNF-α, interleukin-6, malondialdehyde, glucose-lowering medications, oral antidiabetic drugs, insulin, cardioprotection, pleiotropy, cardiovascular risk reduction, glycemic control, hypolipidemic effect, antithrombotic activity
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, C-Reactive Protein, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Inflammation, Tumor Necrosis Factor-alpha, Biomarkers, Randomized Controlled Trials as Topic, Oxidative Stress

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.3389/fendo.2025.1734549
The paper
Alrasheed, T., Mostafa, M. E. A., Madkhali, M. A., & Khairy, H. A. (2026). Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2025.1734549

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.